Furmonertinib, as a novel 3rd-generation EGFR-TKI, demonstrates excellent clinical efficacy, a good safety profile, and a wide therapeutic window (80mg–240 mg) in advanced NSCLC with EGFR classical and CNS metastases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.